Printer Friendly

/C O R R E C T I O N -- LIDAK PHARMACEUTICALS/

 In NY024, Lidak Pharmaceuticals Announces Third Quarter Financial Results, moved earlier today, we are advised by a representative of the company that the figures in the Condensed Balance Sheet Data under 6/30/92 are incorrect. A corrected version of the entire balance sheet follows:
 Condensed Balance Sheet Data:
 Nine months ended 6/30/93 6/30/92
 Cash, cash equivalent and
 short-term investments $9,459,051 $11,220,064
 Working capital 9,182,692 10,914,278
 Total assets 10,009,103 11,488,024
 Total liabilities 418,033 324,816
 Stockholder's equity 9,591,070 11,163,208
 -0- 8/13/93 C NY024
 /PRNewswire -- Aug. 13/


CO: LIDAK Pharmaceuticals ST: California IN: MTC SU: ERN

LG -- NY024A -- 2651 08/13/93 15:18 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 13, 1993
Words:127
Previous Article:SPECTRASCIENCE INSTITUTES CASH CONSERVATION MEASURES, COMPLETING PRODUCT DEVELOPMENT ACTIVITIES
Next Article:RJR NABISCO, INC. SENIOR NOTES RATED 'BBB' BY DUFF & PHELPS, REMAINS ON RATING WATCH -- UNFAVORABLE
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters